The joint AI drug development venture between GlaxoSmithKline and AI start-up Centaur Chemist AI says it has delivered its first results with a potential treatment for chronic obstructive pulmonary disorder. The therapy was developed through Centaur Chemist AI’s Exscientia platform. The use of AI in drug development is considered to be in its infancy although a number of drug manufacturers have expressed interest. AI is seen as accelerating development and providing the ability to find new targets that existing methods could miss.
The joint AI drug development venture between GlaxoSmithKline and AI start-up Exscientia says it has delivered its first results with a potential treatment for chronic obstructive pulmonary disorder. The therapy was developed through Exscientia’s Centaur Chemist AI platform. The use of AI in drug development is considered to be in its infancy although a number of drug manufacturers have expressed interest. AI is seen as accelerating development and providing the ability to find new targets that existing methods could miss.